pharmaphorum4d
Libtayo gets a double with EU approvals in skin, lung cancer
The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...
pharmaphorum5d
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
There's no shortage of cancer immunotherapies trying ... Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months ...
CURE4d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
FiercePharma10d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...
PMLiVE1mon
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
With these results, Libtayo now has the potential to also transform the treatment of high-risk resectable CSCC with adjuvant treatment.” Lead C-POST investigator, Danny Rischin, the Peter MacCallum ...
Business Insider8d
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...